Skip to contentpdufa.bio

z-basivarsen (DYNE-101)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

z-basivarsen (DYNE-101) is a Dyne Therapeutics, Inc. program in myotonic dystrophy type 1 (DM1). Its next catalyst is a Readout in Q1 2027.

DYN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Myotonic dystrophy type 1 (DM1). Sponsor: Dyne Therapeutics, Inc. (DYN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027DYN

Specialist biotech funds holding DYN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors1,265,362$20.4 millionfiled November 16, 2026
Baker Bros. Advisors813,449$13.1 millionfiled November 16, 2026
RTW Investments300,000$4.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is z-basivarsen (DYNE-101)'s next FDA decision or readout?

The next tracked catalyst for z-basivarsen (DYNE-101) is a Readout in Q1 2027.

What happened at z-basivarsen (DYNE-101)'s most recent FDA decision?

No FDA decision for z-basivarsen (DYNE-101) is in our archive yet.

What is z-basivarsen (DYNE-101) used for?

In our records z-basivarsen (DYNE-101) is under review or in development for Myotonic dystrophy type 1 (DM1).

Who makes z-basivarsen (DYNE-101)?

Dyne Therapeutics, Inc. (DYN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.